General
Preferred name
MICAFUNGIN
Synonyms
Mycamine ()
Micafungin (sodium salt) ()
P&D ID
PD009783
CAS
235114-32-6
208538-73-2
Tags
natural product
drug
available
Drug Status
investigational
approved
Drug indication
Candidiasis
Max Phase
Phase 4
First approval
2005
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.; ; Indicated for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
Compound Sets
10
Bioprocess diversity set
Cayman Chemical Bioactives
18009
ChEMBL Approved Drugs
CHEMBL457547
ChEMBL Drugs
CHEMBL457547
Drug Repurposing Hub
DrugBank
DB01141
DrugBank Approved Drugs
DB01141
DrugMAP
DM6Y3AN
DrugMAP Approved Drugs
DM6Y3AN
NCATS Inxight Approved Drugs
R10H71BSWG
External IDs
31
Properties
(calculated by RDKit )
Molecular Weight
1269.44
Hydrogen Bond Acceptors
23
Hydrogen Bond Donors
16
Rotatable Bonds
18
Ring Count
7
Aromatic Ring Count
4
cLogP
-3.9
TPSA
510.14
Fraction CSP3
0.48
Chiral centers
15.0
Largest ring
21.0
QED
0.03
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Biological process
Cell polarity & morphogenesis
Indication
candidemia, peritonitis, esophageal candidiasis
MOA
fungal 1,3-beta-D-glucan synthase inhibitor
Therapeutic Class
Antifungal Agents
Source data